CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that it will give an oral presentation at the 35th International Conference On Antiviral Research (ICAR) 2022, to be held in Seattle and virtually from March 21-25 2022.
Details of Pardes’ oral presentation:
Title: Profile of PBI-0451 an Orally Administered 3CL Protease Inhibitor of SARS-CoV-2 for COVID-19
Presentation Date: Thursday, March 24, 2022
Session: Coronaviruses (2:45-5:45 p.m. PT)
Registered attendees will be able to view the presentation session on the ICAR virtual platform, which will be available live or on-demand through April 25, 2022.
About Pardes Biosciences, Inc.
Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates. For more information, please visit www.pardesbio.com.
Availability of Other Information about Pardes Biosciences
Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure). Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes’ press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.
Investor Contact:
ir@pardesbio.com
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
